Growing concerns over the safety and
efficacy of anti-depressant drugs prescribed to children have caught the eye of
Congress and the New York state attorney general. Now they’re becoming the
catalyst for calls to reform the way clinical trials of all drugs are
reported. Pressure is already causing some changes within the
pharmaceutical industry. And it has put the US Food and Drug Administration
(FDA), which approves new drugs, in the hot seat. If reforms are carried out,
they could bring an unprecedented level of transparency to drug
research. The solution now under consideration: a public
database, or registry, of drug trials, where companies would post the results of
those trials. In congressional testimony Thursday, a spokesman
for the American Medical Association endorsed the registry A. They are very transparent in reporting the results of the tests. B. They have reached an agreement with Congress. C. Sometimes they hold back unfavorable results. D. They are willingly to post a drug trial in a public database.
更多"{{B}}TEXT C{{/B}}
Growi"的相关试题:
[单项选择] {{B}}TEXT C{{/B}}
Growing concerns over the safety and
efficacy of anti-depressant drugs prescribed to children have caught the eye of
Congress and the New York state attorney general. Now they’re becoming the
catalyst for calls to reform the way clinical trials of all drugs are
reported. Pressure is already causing some changes within the
pharmaceutical industry. And it has put the US Food and Drug Administration
(FDA), which approves new drugs, in the hot seat. If reforms are carried out,
they could bring an unprecedented level of transparency to drug
research. The solution now under consideration: a public
database, or registry, of drug trials, where companies would post the results of
those trials. In congressional testimony Thursday, a spokesman
for the American Medical Association endorsed the registry A. Growing concerns over the safety and efficacy of anti-depressant drugs prescribed to children. B. The requirements of Congress and the New York state attorney general. C. Changes within the pharmaceutical industry. D. The information provided by a dozen influential medical journals.
[单项选择] {{B}}TEXT C{{/B}}
Growing concerns over the safety and
efficacy of anti-depressant drugs prescribed to children have caught the eye of
Congress and the New York state attorney general. Now they’re becoming the
catalyst for calls to reform the way clinical trials of all drugs are
reported. Pressure is already causing some changes within the
pharmaceutical industry. And it has put the US Food and Drug Administration
(FDA), which approves new drugs, in the hot seat. If reforms are carried out,
they could bring an unprecedented level of transparency to drug
research. The solution now under consideration: a public
database, or registry, of drug trials, where companies would post the results of
those trials. In congressional testimony Thursday, a spokesman
for the American Medical Association endorsed the regi A. Growing concerns over the safety and efficacy of anti-depressant drugs prescribed to children. B. The requirements of Congress and the New York state attorney general. C. Changes within the pharmaceutical industry. D. The information provided by a dozen influential medical journals.
[单项选择] {{B}}TEXT C{{/B}} Growing concerns over the
safety and efficacy of anti-depressant drugs prescribed to children have caught
the eye of Congress and the New York state attorney general. Now they’re
becoming the catalyst for calls to reform the way clinical trials of all drugs
are reported. Pressure is already causing some changes within
the pharmaceutical industry. And it has put the US Food and Drug Administration
(FDA), which approves new drugs, in the hot seat. If reforms are carried out,
they could bring an unprecedented level of transparency to drug
research. The solution now under consideration: a public
database, or registry, of drug trials, where companies would post the results of
those trials. In congressional testimony Thursday, a spokesman
for the American Medical Association endorsed the registry and said it should
include information on each trial’ s purpose and objective, its design, and the
dates i A. Growing concerns over the safety and efficacy of anti-depressant drugs prescribed to children. B. The requirements of Congress and the New York state attorney general. C. Changes within the pharmaceutical industry. D. The information provided by a dozen influential medical journals.
[单项选择]New concerns about growing religious tension in northern India were ______ this week after at least fifty people were killed and hundreds were injured or arrested in rioting between Hindus and Moslems. A. lessened B. invalidated C. restrained D. dispersed E. fueled
[单项选择]Growing concerns over the safety and efficacy of anti-depressant drugs prescribed to children have caught the eye of Congress and the New York state attorney general. Now they’re becoming the catalyst for calls to reform the way clinical trials of all drugs are reported. Pressure is already causing some changes within the pharmaceutical industry. And it has put the US Food and Drug Administration (FDA), which approves new drugs, in the hot seat. If reforms are carried out, they could bring an unprecedented level of transparency to drug research. The solution now under consideration: a public database, or registry, of drug trials, where companies would post the results of those trials. In congressional testimony Thursday, a spokesman for the American Medical Association endorsed the registry and said it should include information on each trial’s purpose and objective, its design, and the dates it begins and ends. If the trial is not completed, the registry should include A. The pharmaceutical industry. B. US Food and Drug Administration. C. The Congress. D. The drug companies.
购买搜题卡查看答案
[会员特权] 开通VIP, 查看 全部题目答案
[会员特权] 享免全部广告特权
请选择支付方式
-
微信支付
-
支付宝支付
立即支付
系统将自动为您注册账号
请使用微信扫码支付
截图扫码使用小程序[完全免费查看答案]
请不要关闭本页面,支付完成后请点击【支付完成】按钮
恭喜您,购买搜题卡成功
重要提示:请拍照或截图保存账号密码!
我要搜题网官网:https://www.woyaosouti.com
我已记住账号密码
| | |